(Date:7/18/2008)...state-of-the-art radiation technology ...ER, Texas, July 18 /PRNewswire/ -- Patients of Tri...as Oncology-Tyler are among the first,in the natio...ipment that,provides faster and more accurate trea...p://www.newscom.com/cgi-bin/prnh/20061117/DAF023LO...
(Date:7/18/2008)...the University of Pennsylvania School of Medicine ...ed with familial Alzheimer,s disease disrupt the f...ns, called PS1 and PS2 (presenilin 1 and 2), inter...ular cell compartment. , "The ,calcium dysregula...al Alzheimer,s disease has been suggested by previ...
(Date:7/18/2008)...istance to chemotherapy drugs, sometimes abruptly,...ing well to reduce tumors or hold them in check? ...lt when this occurs is all too familiar: patients ...ecome resistant. , A team of researchers at Cold...stand the genetic underpinnings of cancer therapy ...
(Date:7/18/2008)...wswire-USNewswire/ -- William S.,Harris, Ph.D., FA...ter,dated July 16:, Eating fish, especially oily...heart disease prevention. Fish is low in total and...ce minerals, and contains,long-chain omega-3 fatty...thy omega-3s include salmon, trout, albacore tuna,...
Breaking Medicine News(10 mins):Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 2Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 3Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 4Health News:Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology 5Health News:Calcium may be the key to understanding Alzheimer's disease 2Health News:Calcium may be the key to understanding Alzheimer's disease 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 2Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 3...ed by doctors and dentists according to a report r...rowa€?s Furness General Hospital is rated as good ...undly criticised the NHS services in Cumbria. The ... conducted by it is far more wide-ranging and toug...
...e neo-natal intensive care unit of the Rizal Medic...//effect was passed by the Philippine Health Secre...death of seven new born babies. The unfortunate d...rtified by the hospital to have occurred due to un...
...phenomenal rise in sexually transmitted diseases i...f the most common treatable sexually transmitted d...d to have increased four-fold in its incidence rat...ith new cases having been reported in both older a...
...erous, more so because its look and perception spe...lt’ status, and is becoming the life of many parti...that the hookah or the pipe is indeed a wolf in sh...redo, director of the Cancer Genetics and Epidemio...
Other Medicine News:Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2(Date:7/16/2008)... Raptor to Support Phase 2a Clinical Trial at UCSD...-- Raptor,Pharmaceuticals Corp. ("Raptor" or the "...ced the execution of a collaboration agreement (th...San Diego ("UCSD") to,include a Phase 2a clinical ... cysteamine bitartrate ("Cysteamine") in adolescen...
(Date:7/15/2008)... Fund Completion of Phase III Trials of Light Infu...tatic Colorectal Cancer and Phase I/II a... BELLEVUE, Wash., July 15 /- Light S...pany developing Light Infusion Therapy(TM),(Litx(T...nounced that it,has raised $40.1 million in a Seri...
(Date:7/15/2008)...Reports 92 Percent Response Rate to Combination Tr...ll/ -- Cephalon, Inc. (Nasdaq:,CEPH) announced tod...in the,Journal of Clinical Oncology, 92 percent of... cell non-Hodgkin,s lymphoma (NHL) responded to tr...e) for Injection plus rituximab.,This combination ...
(Date:7/14/2008)... VIEW, Calif., July 14 /- M...nounced it has initiated its,Phase 3 clinical prog...or,migraine., MAP0004 is orally inhaled and self-...oprietary Tempo(R) inhaler. In the company,s prior...ief in as fast as 10 minutes,with relief sustaine...
Breaking Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Light Sciences Oncology Raises $40.1 Million in Series C Financing 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 1American Chemical Societys Weekly PressPac Feb 6 2008 11486 2American Chemical Societys Weekly PressPac Feb 6 2008 11486 3American Chemical Societys Weekly PressPac Feb 6 2008 11486 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 5American Chemical Societys Weekly PressPac Feb 6 2008 11486 6American Chemical Societys Weekly PressPac Feb 6 2008 11486 7American Chemical Societys Weekly PressPac Feb 6 2008 11486 8American Chemical Societys Weekly PressPac Feb 6 2008 11486 9FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 1FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 2...ne 4, 2007 – Data presented,today at this ye...ASCO) meeting in Chicago show that a novel combina...uorouracil (5-FU) therapy UFT,(tegafur–uraci...ponse rate in the first-line treatment of metastat...(Study of CPT-11 with Oxaliplatin combined,with UF...
...ne 4, 2007 – Genta,Incorporated (Nasdaq: GNT...ase 2 clinical trial of its marketed product, Gani...b (Rituxan®;,Genentech/IDEC) and dexamethasone...in’s lymphoma (NHL). The data were,presented...Clinical,Oncology (ASCO) in Chicago, IL. , ,Previo...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: